ketoconazole has been researched along with Leukemia, Myeloid, Acute in 17 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia." | 2.90 | Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. ( Gammon, G; Kankam, M; Li, J; Trone, D, 2019) |
| " and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL." | 2.67 | Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ( Bradford, CR; Copplestone, JA; Prentice, AG; Warnock, DW, 1991) |
| "Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)." | 1.56 | Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ( Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020) |
| " capitatum are usually sensitive to the azole compounds the explanation may be a too low daily dosage for the treatment of severely immunocompromised hosts." | 1.28 | [Trichosporon capitatum septicemia in immunosuppressed patients]. ( Bergerat, JP; Dufour, P; Herbrecht, R; Koenig, H; Liu, KL; Maloisel, F; Oberling, F; Waller, J, 1990) |
| "A patient with acute myeloid leukemia (AML) who developed probable aspergillosis of the lung underwent partial lobectomy prior to allogeneic bone marrow transplantation (BMT)." | 1.27 | Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. ( Cohen, O; De Pauw, BE; De Vries, F; De Witte, T; Donnelly, JP; Schattenberg, A, 1988) |
| " The half-life of ketoconazole was 3." | 1.27 | Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ( Bredow, MT; Daneshmend, TK; Richardson, MD; Slade, RR; Stockley, RJ; Warnock, DW, 1986) |
| "Hepatic candidiasis has been increasingly recognized as a variant of disseminated candidiasis in immunocompromised patients." | 1.27 | Hepatic candidiasis: an increasing problem in immunocompromised patients. ( Feld, R; Haron, E; Hasselback, R; Matlow, A; Patterson, B; Tuffnell, P, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Prakash, C | 1 |
| Fan, B | 1 |
| Ke, A | 1 |
| Le, K | 1 |
| Yang, H | 1 |
| Li, J | 1 |
| Kankam, M | 1 |
| Trone, D | 1 |
| Gammon, G | 1 |
| Rusthoven, JJ | 1 |
| Feld, R | 2 |
| Tuffnell, PG | 1 |
| Vreugdenhil, G | 1 |
| Raemaekers, JM | 1 |
| van Dijke, BJ | 1 |
| de Pauw, BE | 2 |
| Walsh, M | 1 |
| White, L | 1 |
| Atkinson, K | 1 |
| Enno, A | 1 |
| Hendriks, WD | 1 |
| Sizoo, W | 1 |
| Palmblad, J | 1 |
| Lönnqvist, B | 1 |
| Carlsson, B | 1 |
| Grimfors, G | 1 |
| Järnmark, M | 1 |
| Lerner, R | 1 |
| Ljungman, P | 1 |
| Nyström-Rosander, C | 1 |
| Petrini, B | 1 |
| Oberg, G | 1 |
| Barantsevich, EP | 1 |
| Karaev, ZO | 1 |
| Bradford, CR | 1 |
| Prentice, AG | 1 |
| Warnock, DW | 2 |
| Copplestone, JA | 1 |
| Herbrecht, R | 1 |
| Liu, KL | 1 |
| Koenig, H | 1 |
| Waller, J | 1 |
| Dufour, P | 1 |
| Maloisel, F | 1 |
| Bergerat, JP | 1 |
| Oberling, F | 1 |
| McNulty, RM | 1 |
| Lazor, JA | 1 |
| Sketch, M | 1 |
| Schattenberg, A | 1 |
| De Vries, F | 1 |
| De Witte, T | 1 |
| Cohen, O | 1 |
| Donnelly, JP | 1 |
| Garavelli, PL | 1 |
| Michelone, G | 1 |
| Cavanna, C | 1 |
| Maccabruni, A | 1 |
| Stockley, RJ | 1 |
| Daneshmend, TK | 1 |
| Bredow, MT | 1 |
| Richardson, MD | 1 |
| Slade, RR | 1 |
| Haron, E | 1 |
| Tuffnell, P | 1 |
| Patterson, B | 1 |
| Hasselback, R | 1 |
| Matlow, A | 1 |
| von Paleske, A | 1 |
| Müllerleile, U | 1 |
| Gressler, V | 1 |
| Garbrecht, M | 1 |
| Hossfeld, DK | 1 |
| Dandona, P | 1 |
| Mohiuddin, J | 1 |
| Prentice, HG | 1 |
4 trials available for ketoconazole and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; Benzothiazoles; Cytoch | 2019 |
Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Itraconazole; Ketoconazole; Leukemia, Myeloid, A | 1993 |
Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candidiasis; Humans; Incidence; Ketocona | 1992 |
Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Humans; Itraconazole; Ketoconazole; | 1991 |
13 other studies available for ketoconazole and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 | 2020 |
Systemic infection by Rhodotorula spp. in the immunocompromised host.
Topics: Adult; Amphotericin B; Bone Marrow; Flucytosine; Humans; Ketoconazole; Leukemia, Myeloid, Acute; Liv | 1984 |
Fungal Pseudoallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Drug Resistance, Microbial; Humans; Itraconazo | 1992 |
Possible failure of itraconazole in preventing fungal infection in a neutropenic leukaemia patient.
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Aspergillus niger; Humans; Itraconazole; Ke | 1992 |
[Esophageal candidiasis in patients with hemoblastosis].
Topics: Candidiasis; Diagnosis, Differential; Esophageal Diseases; Female; Humans; Ketoconazole; Leukemia, M | 1992 |
[Trichosporon capitatum septicemia in immunosuppressed patients].
Topics: Adult; Female; Fluconazole; Humans; Immune Tolerance; Ketoconazole; Leukemia, Myeloid, Acute; Male; | 1990 |
Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy.
Topics: Aged; Candidiasis; Creatinine; Digoxin; Drug Interactions; Humans; Ketoconazole; Leukemia, Myeloid, | 1989 |
Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung.
Topics: Adult; Amphotericin B; Aspergillosis; Bone Marrow Transplantation; Female; Humans; Itraconazole; Ket | 1988 |
[Incidence of mycotic infections in children with acute myeloblastic leukemia (AML)].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Child; Clotrimazole; Drug Resistance, Micro | 1988 |
Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy.
Topics: Adult; Drug Administration Schedule; Female; Half-Life; Humans; Immune Tolerance; Ketoconazole; Kine | 1986 |
Hepatic candidiasis: an increasing problem in immunocompromised patients.
Topics: Adult; Amphotericin B; Biopsy; Candida; Candidiasis; Drug Therapy, Combination; Female; Flucytosine; | 1987 |
Incidence and treatment of fungal infections in neutropenic patients.
Topics: Agranulocytosis; Amphotericin B; Female; Humans; Ketoconazole; Leukemia, Lymphoid; Leukemia, Myeloid | 1987 |
Non-suppression of cortisol secretion by long term treatment with ketoconazole in patients with acute leukaemia.
Topics: Adult; Aged; Cosyntropin; Humans; Hydrocortisone; Ketoconazole; Leukemia, Lymphoid; Leukemia, Myeloi | 1985 |